CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
- Conditions
- Fontan CirculationSingle Ventricle Heart DiseaseHFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo Tablet
- Registration Number
- NCT06762964
- Lead Sponsor
- Mayo Clinic
- Brief Summary
- The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 27
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
- Group - Intervention - Description - Dapagliflozin - Dapagliflozin tablet - - - Placebo - Placebo Tablet - - 
- Primary Outcome Measures
- Name - Time - Method - Pulmonary capillary wedge pressure (PCWP) at rest - Baseline, 24 Months - Pulmonary Capillary Wedge pressure will be determined by right heart catheterization with expired gas analysis. Right heart catheterization with expired gas analysis will be performed at rest. Pulmonary Capillary Wedge Pressure is measured in millimeters of mercury (mmHg). - Pulmonary capillary wedge pressure with feet elevated - Baseline, 24 Months - Pulmonary Capillary Wedge pressure will be determined by right heart catheterization with expired gas analysis. Right heart catheterization with expired gas analysis will be performed with feet elevated. Pulmonary Capillary Wedge Pressure is measured in millimeters of mercury (mmHg). - Pulmonary capillary wedge pressure at 20W exercise - Baseline, 24 Months - Pulmonary Capillary Wedge pressure will be determined by right heart catheterization with expired gas analysis. Right heart catheterization with expired gas analysis will be performed at 20W exercise. Pulmonary Capillary Wedge Pressure is measured in millimeters of mercury (mmHg). 
- Secondary Outcome Measures
- Name - Time - Method - Right atrial pressure at rest - Baseline, 24 Months - Right atrial pressure at rest will be determined by right heart catheterization with expired gas analysis. Right heart catheterization with expired gas analysis will be performed at rest. Right atrial pressure will be measured in millimeters of mercury (mmHg). - Right atrial pressure with exercise - Baseline, 24 Months - Right atrial pressure at rest will be determined by right heart catheterization with expired gas analysis. Right heart catheterization with expired gas analysis will be performed with exercise. Right atrial pressure will be measured in millimeters of mercury (mmHg). - Pulmonary artery pressures at rest - Baseline, 24 Months - Pulmonary artery pressures will be determined by right heart catheterization with expired gas analysis. Pulmonary artery pressures with expired gas analysis will be performed at rest. Pulmonary artery pressures will be measured in millimeters of mercury (mmHg). - Pulmonary artery pressures with exercise - Baseline, 24 Months - Pulmonary artery pressures will be determined by right heart catheterization with expired gas analysis. Pulmonary artery pressures with expired gas analysis will be performed with exercise. Pulmonary artery pressures will be measured in millimeters of mercury (mmHg). - Cardiac output at rest - Baseline, 24 Months - Cardiac output measures the amount of blood the heart pumps per minute. It is calculated by Cardiac Output= Oxygen Consumption/(Arterial - Venous Oxygen Content Difference). Cardiac output will be measured in liters per minute (L/min). - Cardiac output with exercise - Baseline, 24 Months - Cardiac output measures the amount of blood the heart pumps per minute. It is calculated by Cardiac Output= Oxygen Consumption/(Arterial - Venous Oxygen Content Difference). Cardiac output will be measured in liters per minute (L/min). - Peak oxygen consumption (VO2) during exercise - Baseline, 24 Months - Peak oxygen consumption (VO2) is measured in milliliters of oxygen per minute (mL/min). - Change in plasma volume - Baseline, 24 Months - Plasma volume will be determined by radiolabeled iodinated albumin (131I, 5-25 μCu) indicator dilution technique (BVA-100 Blood Volume Analyzer, Daxor Corp, NY). Plasma volume will be measured in milliliters (mL). - Change in blood volume - Baseline, 24 Months - Blood volume will be determined by radiolabeled iodinated albumin (131I, 5-25 μCu) indicator dilution technique (BVA-100 Blood Volume Analyzer, Daxor Corp, NY). Blood volume will be measured in milliliters (mL). - SF-36 quality of life (QOL) - Baseline, 24 Months - SF-36 quality of life (QOL) questionnaire is a 36-question questionnaire that evaluates a patient's quality of life. The score range is from 0-100, with a higher score reflecting a better quality of life. - Change in fat mass - Baseline, 24 Months - Fat mass will be determined by Dual Energy X-ray Absorptiometry Scan. Fat mass will be measured in kilograms (kg). - Change in fat free mass - Baseline, 24 Months - Fat free mass will be determined by Dual Energy X-ray Absorptiometry Scan. Fat free mass will be measured in kilograms (kg). 
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
- Mayo Clinic 🇺🇸- Rochester, Minnesota, United States Mayo Clinic🇺🇸Rochester, Minnesota, United StatesLuke Burchill, M.B.B.S., Ph.D.Principal Investigator
